DEA - Biden Considers Marijuana Rescheduling: Boon Or Bust For The Industry? Former Top FDA Official Weighs In | Benzinga
Many observers agree that President Joe Biden's administration is poised for a historic shift in federal drug policy, that is loosening cannabis restrictions through potential rescheduling.
But the move, while seemingly a step towards legalization, has sparked concerns from unexpected corners: legalization advocates themselves.
While proponents see rescheduling as a step towards legalization, some critics argue it lacks the force necessary to mend the federal-state divide, fails to address the impacts of criminalization and could pave the way for pharmaceutical giants to hijack the medical marijuana industry, squeezing out smaller, state-licensed producers.
However, Howard Sklamberg, a legal expert and former top official at the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research, dismisses these anxieties. In an exclusive interview with Politico’s Mona Zhang published on New Year’s Day, he argued that rescheduling would benefit the cannabis industry in several ways.
Rescheduling would unlock financial growth ...